Efficacy and Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Monocytic Leukemia Patients.
10.19746/j.cnki.issn.1009-2137.2020.06.012
- Author:
Wan-Ying PAN
1
;
Ke-Xin LI
1
;
Shao-Jie WU
1
;
Ya-Ling ZHENG
1
;
Lan DENG
1
;
Rui HUANG
1
;
San-Fang TU
1
;
Chao-Yang SONG
1
;
Yu-Hua LI
2
;
Yu-Xian HUANG
3
Author Information
1. Department of Hematology, Zhujiang Hospital Affiliated to Southern Medical University, Guangzhou 510282, Guangdong Province, China.
2. Department of Hematology, Zhujiang Hospital Affiliated to Southern Medical University, Guangzhou 510282, Guangdong Province, China,E-mail: liyuhua2011gz@163.com.
3. Department of Hematology, Zhujiang Hospital Affiliated to Southern Medical University, Guangzhou 510282, Guangdong Province, China,E-mail: hyx6610@163.com.
- Publication Type:Journal Article
- MeSH:
Child;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Monocytic, Acute;
Leukemia, Myeloid, Acute;
Patients;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2020;28(6):1859-1866
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of acute monocytic leukemia (AML-M5) and the related factors that affecting the prognosis of the patients.
METHODS:The clinical data of 71 patients with AML-M5 treated with allo-HSCT in Zhujiang Hospital Affiliated to Southern Medical University from April 2009 to October 2019 were collected and retrospectively analyzed. The incidence of graft-versus-host disease (GVHD), cumulative overall survival (OS) rate, cumulative progression-free survival (PFS) rate, transplantation-related mortality (TRM), relapse rate and the risk factors affecting prognosis in the patients were analyzed.
RESULTS:66 patients obtained hematopoietic reconstruction after transplantation, the median time of granulocyte implantation was 12 (9-26) d, and the median time of megakaryocytic implantation was 13 (8-72) d. The incidence of acute GVHD and chronic GVHD was 33.8% (24/71) and 36.6% (26/71), respectively. The median follow-up time was 13.81 (0.16 to 112.54) months; the median OS and PFS was 31.27 and 26.07 months, respectively. The cumulative OS of the patients in 1 and 3 years after transplantation was 64.9% and 48.6%, respectively, and the cumulative PFS of the patients in 1 and 3 years was 55.0% and 39.5%, respectively. The cumulative relapse rate of the patients in 1 and 3 years was 24% and 40%, respectively. Multivariate analysis showed that pre-transplantation relapse was the independent risk factor affecting OS (HR=2.32, 95%CI:1.17-4.62, P=0.02) and PFS (HR=3.08, 95%CI:1.61-5.90, P=0.001) of the patients; invasive fungal disease after transplantation was the independent risk factor affecting OS (HR=2.71, 95% CI:1.32-5.56, P=0.007) and PFS (HR=2.87, 95%CI=1.40-5.86, P=0.004) of the patients; FLT3 mutation was the independent risk factor affecting PFS (HR=2.13, 95%CI=1.07-4.24, P=0.03) of the patients.
CONCLUSION:AML-M5 is the intermediate or high-risk leukemia, and allo-HSCT can improve the survival prognosis of the patients. Pre-transplantation relapse and invasive fungal disease after transplantation are the important factors affecting the efficacy of allo-HSCT in patients with AML-M5.
